Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence
Posted inClinical Updates news Oncology Urology

Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence

Comprehensive review of metformin's role in metastatic prostate cancer with ADT highlights STAMPEDE trial's findings: no significant overall survival benefit but metabolic side-effect mitigation. Integration of other RCTs outlines nuanced effects on metabolic syndrome and progression outcomes.
Visual Whole-Body Tumor-Burden Classification via PSMA PET/CT: Advancing Prognostic Stratification and Therapy Response Prediction in Metastatic Hormone-Sensitive Prostate Cancer
Posted innews Oncology Radiology Urology

Visual Whole-Body Tumor-Burden Classification via PSMA PET/CT: Advancing Prognostic Stratification and Therapy Response Prediction in Metastatic Hormone-Sensitive Prostate Cancer

A novel PSMA PET/CT-based tumor-burden classification effectively stratifies metastatic hormone-sensitive prostate cancer patients, predicting response and prognosis with androgen receptor signaling inhibitors, especially second-generation treatments.